BRENDA home
History
Information on EC 3.4.11.3 - cystinyl aminopeptidase
for references in articles please use BRENDA:EC3.4.11.3Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
3.4.11.3 cystinyl aminopeptidaseSpecify your search results
Word Map
- 3.4.11.3
- envelope
- pregnancy
- cd4
- epitope
- lymphocyte
- angiotensin
- viruses
- vaccinia
- women
-
humoral
-
hiv-1-infected
- aminopeptidases
- t-cells
- virion
-
simian
- macaque
-
hiv-specific
-
seronegative
-
immunodominant
-
syncytium
- furin
-
seropositive
-
prime-boost
- nef
- seroconversion
-
vaccinees
-
anti-hiv-1
- insipidus
- chimpanzee
-
hiv-seronegative
- desmopressin
-
ddavp
-
sivmac239
-
alum
-
glut4-containing
- shiv
-
oligosaccharyltransferase
-
intrarectal
- medicine
-
1-infected
-
nephrogenic
-
non-neutralizing
-
cross-neutralizing
- diagnostics
-
cross-presentation
-
virus-neutralizing
- pharmacology
-
seroconverted
-
vaccine-induced
-
anti-cd4
-
hiv-1iiib
-
radioimmunoprecipitation
-
coreceptors
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria
Reaction Schemes
Release of an N-terminal amino acid, Cys-/-Xaa-, in which the half-cystine residue is involved in a disulfide loop, notably in oxytocin or vasopressin. Hydrolysis rates on a range of aminoacyl arylamides exceed that for the cystinyl derivative, however
Synonyms
alpha-Aminoacyl-peptide hydrolase, aminopeptidase, cystyl, AT4 receptor, CAP, CAP-I, CAP-II, CysAP, cysteine aminopeptidase, cystine aminopeptidase, Cystinyl aminopeptidase, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
alpha-Aminoacyl-peptide hydrolase
-
-
-
-
aminopeptidase, cystyl
-
-
-
-
AT4 receptor
CAP-I
-
-
-
-
CAP-II
-
-
-
-
CysAP
cysteine aminopeptidase
-
-
-
-
cystine aminopeptidase
Cystinyl aminopeptidase
cystinylaminopeptidase
cystyl aminopeptidase
-
-
-
-
cystyl-aminopeptidase
GP160
insulin-regulated aminopeptidase
Insulin-regulated membrane aminopeptidase
Insulin-responsive aminopeptidase
IRAP
L-cystine aminopeptidase
-
-
-
-
LeuAP
LNPEP
OTase
-
-
-
-
oxytocin peptidase
-
-
-
-
oxytocinase
oxytocinase/vasopressinase-like leucyl-cystinyl aminopeptidase LNPEP
-
P-LAP
P-LAP/IRAP
Placental leucine aminopeptidase
placental leucine aminopeptidase/oxytocinase
placental leucine aminopeptidase/oxytocinase/insulin-regulated membrane aminopeptidase
-
-
vasopressinase
vasopresssinase
-
-
-
-
Vesicle protein of 165 kDa
-
-
-
-
Vp165
yscXVI
-
-
-
-
cystine aminopeptidase
-
-
-
-
Cystinyl aminopeptidase
-
-
-
-
GP160
-
-
-
-
Insulin-regulated membrane aminopeptidase
-
-
-
-
Insulin-responsive aminopeptidase
-
-
-
-
IRAP
-
-
-
-
oxytocinase
-
-
-
-
P-LAP
-
-
-
-
Placental leucine aminopeptidase
-
-
-
-
Placental leucine aminopeptidase
-
-
Vp165
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
Release of an N-terminal amino acid, Cys-/-Xaa-, in which the half-cystine residue is involved in a disulfide loop, notably in oxytocin or vasopressin. Hydrolysis rates on a range of aminoacyl arylamides exceed that for the cystinyl derivative, however
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
hydrolysis of peptide bond
-
-
exopeptidase, N-terminus amino acid
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
9031-41-8
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
alpha-L-Asp1-Val5-angiotensin II + H2O
beta-Asp1-Val5-angiotensin II
-
transformation to beta form
-
ir
Arg-4-methylcoumaryl-7-amide + H2O
Arg + 7-amino-4-methylcoumarin
-
-
-
?
L-arginine-7-amido-4-methylcoumarin + H2O
L-arginine + 7-amino-4-methylcoumarin
-
-
-
?
L-benzyl-L-cysteine-p-nitroanilide + H2O
L-benzyl-L-cysteine + p-nitroaniline
-
-
-
-
?
L-leucine-7-amido-4-methylcoumarin + H2O
L-leucine + 7-amino-4-methylcoumarin
-
-
-
?
L-leucine-p-nitroanilide + H2O
L-leucine + p-nitroaniline
-
-
-
-
?
leucyl-beta-naphthylamide + H2O
leucine + beta-naphthylamine
-
-
-
?
LGGGGGL + H2O
L-Leu + GGGGGL
hydrolysis of poly-glycine peptides, overview
-
-
?
Lys-4-methylcoumaryl-7-amide + H2O
Lys + 7-amino-4-methylcoumarin
-
-
-
?
Met-4-methylcoumaryl-7-amide + H2O
Met + 7-amino-4-methylcoumarin
-
-
-
?
Peptides + H2O
?
-
enzyme plays a role in general metabolism of peptides during pregnancy
-
-
?
S-benzyl-Cys-4-methylcoumaryl-7-amide + H2O
S-benzyl-Cys + 7-amino-4-methylcoumarin
-
-
-
?
S-benzyl-cysteine-4-methylcoumarin 7-amide + H2O
S-benzyl-cysteine + 7-amino-4-methylcoumarin
-
-
-
-
?
angiotensin III + H2O
?
-
P-LAP/OTase may be involved in maintaining pregnancy homeostasis via metabolizing peptides such as oxytocin and vasopressin
-
-
?
angiotensin III + H2O
?
-
the enzyme plays a role in blood pressure regulation via hydrolyzing vasopressin and angiotensin III
-
-
?
L-Cys-beta-naphthylamide + H2O
L-Cys + beta-naphthylamine
-
-
-
?
L-cystine-di-beta-naphthylamide + 2 H2O
L-cystine + 2 beta-naphthylamine
-
-
-
?
L-cystine-di-beta-naphthylamide + 2 H2O
L-cystine + 2 beta-naphthylamine
in the presence of thiol, the substrate is converted to L-cystine beta-naphthylamide
-
-
?
L-cystine-di-beta-naphthylamide + 2 H2O
L-cystine + 2 beta-naphthylamine
in the presence of thiol, the substrate is converted to L-cystine beta-naphthylamide
-
-
?
L-cystine-di-beta-naphthylamide + 2 H2O
L-cystine + 2 beta-naphthylamine
-
-
-
?
L-cystine-di-p-nitroanilide + H2O
L-cystine + p-nitroaniline
-
-
-
-
?
Leu-4-methylcoumaryl-7-amide + H2O
Leu + 7-amino-4-methylcoumarin
-
-
-
?
oxytocin + H2O
?
-
in the placenta the enzyme is thought to play a role in the prevention of premature labour and maintenance of an adequate blood flow to the uterus
-
-
?
oxytocin + H2O
?
-
P-LAP in HUVEC cells regulates effects of oxytocin with resolution
-
-
?
oxytocin + H2O
?
-
cleavage sites: Cys-/-Tyr-/-Ile-/-Gln-/-Asn-/-Cys-Pro-Leu-Gly-NH2
-
-
?
oxytocin + H2O
?
-
cleavage sites: Cys-/-Tyr-/-Phe-/-Gln-Asn-Cys-Pro-Arg-Gly-NH2
-
-
?
oxytocin + H2O
acyclic peptide + H2O
-
-
tyrosyl-isoleucyl-glutaminyl-asparaginyl-S-(S-cysteine)cysteinyl-prolyl-leucyl-glycinamide, first product
?
oxytocin + H2O
acyclic peptide + H2O
-
cleavage of bond between N-terminal cysteine and adjacent tyrosine
-
-
?
S-benzyl-L-cysteine-p-nitroanilide + H2O
S-benzyl-L-cysteine + p-nitroaniline
-
-
-
-
?
S-benzyl-L-cysteine-p-nitroanilide + H2O
S-benzyl-L-cysteine + p-nitroaniline
-
-
-
-
?
S-benzyl-L-cysteine-p-nitroanilide + H2O
S-benzyl-L-cysteine + p-nitroaniline
-
-
-
-
?
Vasopressin + H2O
?
-
P-LAP/OTase may be involved in maintaining pregnancy homeostasis via metabolizing peptides such as oxytocin and vasopressin
-
-
?
Vasopressin + H2O
?
-
the enzyme plays a role in blood pressure regulation via hydrolyzing vasopressin and angiotensin III
-
-
?
vasopressin + H2O
hydrolyzed vasopressin
-
vasopressin is a physiological substrate
N-terminal processing
-
?
additional information
?
-
-
peptides having proline as the second amino acid residue
-
-
?
additional information
?
-
-
peptides having proline as the second amino acid residue
-
-
?
additional information
?
-
-
peptides having proline as the second amino acid residue
-
-
?
additional information
?
-
-
not: L-Asp-beta-naphthylamide, L-Glu-beta-naphthylamide
-
-
?
additional information
?
-
-
hydrolyses neutral, aromatic, basic and acidic N-terminal amino acids from peptides
-
-
?
additional information
?
-
-
N-terminal aspartic acid bound via its beta-carboxyl group in a peptide bond
-
-
?
additional information
?
-
-
N-terminal aspartic acid bound via its beta-carboxyl group in a peptide bond
-
-
?
additional information
?
-
-
in individuals with type 2 diabetes the insulin-stimulated translocation of IRAP to the cell-surface of muscle and fat cells is impaired. This defect may lead to decreased cleavage and consequently increased action of peptide hormones that are substrates for IRAP. Impaiered IRAP action may thus play a role in the development of complications in type 2 diabetes
-
-
?
additional information
?
-
-
involvement of the enzyme in memory processing. AT4 ligands, upon binding to the catalytic site of insulin-regulated aminopeptidase, enhance spatial learning, facilitate memory retention and retrieval and reverse amnesia
-
-
?
additional information
?
-
-
vasopressinase cannot degrade 1-deamino-8D-arginine vasopressin
-
-
?
additional information
?
-
no activity with 1-deamino-8-D-arginine vasopressin
-
-
?
additional information
?
-
-
no activity with 1-deamino-8-D-arginine vasopressin
-
-
?
additional information
?
-
-
IRAP is required for maintenance of key constituents of endosome-derived vesicles in cardiac muscle cells
-
-
?
additional information
?
-
-
IRAP is involved in glucose transporter GLUT4 storage vesicle trafficking
-
-
?
additional information
?
-
recombinant IRAP bound to TUG, and this interaction is mapped to a short peptide in IRAP which is critical for GLUT4 intracellular retention. TUG controls vesicle translocation by interacting with IRAP as well as GLUT4
-
-
?
additional information
?
-
-
recombinant IRAP bound to TUG, and this interaction is mapped to a short peptide in IRAP which is critical for GLUT4 intracellular retention. TUG controls vesicle translocation by interacting with IRAP as well as GLUT4
-
-
?
additional information
?
-
recombinant IRAP bound to TUG, and this interaction is mapped to a short peptide in IRAP which is critical for GLUT4 intracellular retention. TUG controls vesicle translocation by interacting with IRAP as well as GLUT4
-
-
?
additional information
?
-
-
the enzyme plays an imprtant role for IRAP in reproductive physiology in regulating the action of peptide hormones
-
-
?
additional information
?
-
-
activity is greatly increased in rats with mammary tumors. The activity may be involved in the promotion and progression of breast cancer through oxytocin, vasopressin and/or renin-angiotensin system misregulation
-
-
?
additional information
?
-
-
the enzyme is involved in the metabolism of angiotensin
-
-
?
additional information
?
-
-
the enzyme plays a role as a mediator for the effects of angiotensin IV and related peptides on extracellular dopamine levels in striatum
-
-
?
additional information
?
-
-
the enzyme plays diverse physiological roles in the rat central nervous system
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
Peptides + H2O
?
-
enzyme plays a role in general metabolism of peptides during pregnancy
-
-
?
vasopressin + H2O
hydrolyzed vasopressin
-
vasopressin is a physiological substrate
N-terminal processing
-
?
angiotensin III + H2O
?
-
P-LAP/OTase may be involved in maintaining pregnancy homeostasis via metabolizing peptides such as oxytocin and vasopressin
-
-
?
angiotensin III + H2O
?
-
the enzyme plays a role in blood pressure regulation via hydrolyzing vasopressin and angiotensin III
-
-
?
oxytocin + H2O
?
-
in the placenta the enzyme is thought to play a role in the prevention of premature labour and maintenance of an adequate blood flow to the uterus
-
-
?
oxytocin + H2O
?
-
P-LAP in HUVEC cells regulates effects of oxytocin with resolution
-
-
?
Vasopressin + H2O
?
-
P-LAP/OTase may be involved in maintaining pregnancy homeostasis via metabolizing peptides such as oxytocin and vasopressin
-
-
?
Vasopressin + H2O
?
-
the enzyme plays a role in blood pressure regulation via hydrolyzing vasopressin and angiotensin III
-
-
?
additional information
?
-
-
in individuals with type 2 diabetes the insulin-stimulated translocation of IRAP to the cell-surface of muscle and fat cells is impaired. This defect may lead to decreased cleavage and consequently increased action of peptide hormones that are substrates for IRAP. Impaiered IRAP action may thus play a role in the development of complications in type 2 diabetes
-
-
?
additional information
?
-
no activity with 1-deamino-8-D-arginine vasopressin
-
-
?
additional information
?
-
-
no activity with 1-deamino-8-D-arginine vasopressin
-
-
?
additional information
?
-
-
IRAP is required for maintenance of key constituents of endosome-derived vesicles in cardiac muscle cells
-
-
?
additional information
?
-
-
IRAP is involved in glucose transporter GLUT4 storage vesicle trafficking
-
-
?
additional information
?
-
recombinant IRAP bound to TUG, and this interaction is mapped to a short peptide in IRAP which is critical for GLUT4 intracellular retention. TUG controls vesicle translocation by interacting with IRAP as well as GLUT4
-
-
?
additional information
?
-
-
recombinant IRAP bound to TUG, and this interaction is mapped to a short peptide in IRAP which is critical for GLUT4 intracellular retention. TUG controls vesicle translocation by interacting with IRAP as well as GLUT4
-
-
?
additional information
?
-
recombinant IRAP bound to TUG, and this interaction is mapped to a short peptide in IRAP which is critical for GLUT4 intracellular retention. TUG controls vesicle translocation by interacting with IRAP as well as GLUT4
-
-
?
additional information
?
-
-
the enzyme plays an imprtant role for IRAP in reproductive physiology in regulating the action of peptide hormones
-
-
?
additional information
?
-
-
activity is greatly increased in rats with mammary tumors. The activity may be involved in the promotion and progression of breast cancer through oxytocin, vasopressin and/or renin-angiotensin system misregulation
-
-
?
additional information
?
-
-
the enzyme is involved in the metabolism of angiotensin
-
-
?
additional information
?
-
-
the enzyme plays a role as a mediator for the effects of angiotensin IV and related peptides on extracellular dopamine levels in striatum
-
-
?
additional information
?
-
-
the enzyme plays diverse physiological roles in the rat central nervous system
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Ca2+
Co2+
Mg2+
-
inhibitory effect of EDTA plus 1,10-phenanthroline can be completely reversed by Zn2+. Ca2+ and Mg2+ increase the potency of Zn2+ for this process
Mn2+
Zinc
Zn2+
Ca2+
-
inhibitory effect of EDTA plus 1,10-phenanthroline can be completely reversed by Zn2+. Ca2+ and Mg2+ increase the potency of Zn2+ for this process
Zinc
-
contains the characteristic Zn2+-coordination sequence element, HEXXH-(18-64X)-E
Zinc
-
enzyme contains 1 mol of zinc per mol of enzyme, contains the consensus HEXXH(X)18E motif of zinc-metallopeptidase proteins
Zn2+
-
complete inhibition of the enzyme activity by 0.1 mM EDTA and 0.1 mM 1,10-phenanthroline can be prevented in the presence of 0.04-0.1 mM ZnCl2
Zn2+
-
inhibitory effect of EDTA plus 1,10-phenanthroline can be completely reversed by Zn2+. Ca2+ and Mg2+ increase the potency of Zn2+ for this process
Zn2+
insulin-regulated aminopeptidase (IRAP) is a membrane-bound zinc metallopeptidase
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(2-[[(1-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-prolyl)amino]methyl]phenyl)acetic acid
-
-
(2-[[(1-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-prolyl)amino]methyl]phenyl)acetic acid
-
-
(2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-isoleucyl)amino]methyl]phenyl)acetic acid
-
-
(2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-leucyl)amino]methyl]phenyl)acetic acid
-
-
(2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-isoleucyl)amino]methyl]phenyl)acetic acid
-
-
(2-[[(N-[[3-amino-5-(4-hydroxybenzyl)phenyl]carbonyl]-L-isoleucyl)amino]methyl]phenyl)acetic acid
-
-
1,2-Acyclic oxytocin
-
slight inhibition of oxytocin degradation, marked inhibition of cystine di-beta-naphthylamide degradation
2,2'-bipyridine
-
acetic acid-containing chelators potentiate the inhibitory effect of 2,2'-bipyridine. Efficiacy decreases in the order: diethylenetriamine-N,N,N',N'',N''-pentaacetic acid, EDTA, EGTA
2-[[(1-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-prolyl)amino]methyl]benzoic acid
-
-
2-[[(1-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-prolyl)amino]methyl]benzoic acid
-
-
2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-isoleucyl)amino]methyl]benzoic acid
-
-
2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-leucyl)amino]methyl]benzoic acid
-
-
2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-isoleucyl)amino]methyl]benzoic acid
-
-
4-bromo-2,6-difluoro-N-[3-(1H-tetrazol-5-yl)phenyl]benzene-1-sulfonamide
-
4-bromo-5-chloro-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-carboxamide
-
-
7-chloro-N-[3-(1H-tetrazol-5-yl)phenyl]-1,3-dihydro-2,1,3-benzoxadiazole-4-sulfonamide
-
-
7-chloro-N-[3-(1H-tetrazol-5-yl)phenyl]-2,1,3-benzoxadiazole-4-sulfonamide
-
benzyl N-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-tryptophanate
-
benzyl N-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-valinate
-
benzyl N-(4-amino-3-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-tryptophanate
-
benzyl N-[3-amino-4-([(2S)-2-amino-4-[4-(benzyloxy)phenyl]butanoyl]amino)benzoyl]-L-tryptophanate
-
benzyl N-[3-amino-4-[(O-benzyl-L-tyrosyl)amino]benzoyl]-L-tryptophanate
-
benzyl N-[4-amino-3-[(O-benzyl-L-tyrosyl)amino]benzoyl]-L-tryptophanate
-
cyclohexylmethyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
ethyl 2,7-diamino-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
ethyl 2-acetamido-7-hydroxy-4-(3-quinolinyl)-4H-chromene-3-carboxylate
HFI-437
ethyl 2-amino-4-(2,4-dichloropyridin-3-yl)-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-4-(5,8-dihydroquinolin-2-yl)-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-4-[4-(dimethylamino)phenyl]-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-6-bromo-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
ethyl 2-amino-7-(dimethylamino)-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
ethyl 2-amino-7-(formyloxy)-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
ethyl 2-amino-7-hydroxy-4-(1,3-thiazol-2-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
ethyl 2-amino-7-hydroxy-4-(thiophen-2-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
ethyl 2-amino-7-hydroxy-4-[4-(pyridin-2-yl)phenyl]-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-methoxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
L-Arg-vasopressin
-
Ki-value for wild-type, mutants G428E, G428D, G428Q above 0.03 mM
L-Val-L-Tyr-L-Ile-2-aminomethylphenylacetic acid
-
inhibits both IRAP and aminopeptidase N and induces proliferation of stem cells at low concentrations
L-Val-L-Tyr-L-Ile-L-Cys-L-Pro-L-Cys
-
cyclic disulfide, angiotensin IV analog, considerably more stable than angiotensin IV toward enzymatic degradation
LVV hemorphin 7
LVV-H7, IRAP ligands are on the one hand competitive inhibitors of the enzymatic activity of IRAP and on the other hand regulators of its trafficking
methyl 4-amino-3-([(2S)-2-amino-4-[4-(benzyloxy)phenyl]butanoyl]amino)benzoate
-
methyl 4-amino-3-[[(2S)-2-amino-4-(4-hydroxyphenyl)butanoyl]amino]benzoate
-
methyl N-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-tyrosinate
-
methyl N-(4-amino-3-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-tyrosinate
-
methyl N2-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-argininate
-
methyl N2-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-lysinate
-
methyl N2-(4-amino-3-[[(2S)-2-amino-4-(4-hydroxyphenyl)butanoyl]amino]benzoyl)-L-lysinate
-
methyl N2-(4-amino-3-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-lysinate
-
methyl N2-[4-amino-3-([(2S)-2-amino-4-[4-(benzyloxy)phenyl]butanoyl]amino)benzoyl]-L-lysinate
-
N-(3-(1H-tetrazol-5-yl)phenyl)-2,5-bis(trifluoromethyl)-benzenesulfonamide
-
N-(3-(1H-tetrazol-5-yl)phenyl)-2-fluoro-5-(trifluoromethyl)benzenesulfonamide
-
N-(3-(1H-tetrazol-5-yl)phenyl)-3,5-bis(trifluoromethyl)-benzenesulfonamide
-
N-(3-(1H-tetrazol-5-yl)phenyl)-3-fluoro-4-(trifluoromethyl)benzenesulfonamide
-
N-(3-(1H-tetrazol-5-yl)phenyl)-3-methyl-4-(trifluoromethyl)benzenesulfonamide
-
N-(3-(1H-tetrazol-5-yl)phenyl)-4-methyl-3-(trifluoromethyl)benzenesulfonamide
-
N-(3-amino-4-[[(2S)-2-amino-4-(4-hydroxyphenyl)butanoyl]amino]benzoyl)-L-tryptophan
-
N-(4-amino-3-[[(2R)-2-amino-4-(4-hydroxyphenyl)butanoyl]amino]benzoyl)-L-tryptophan
-
N-hexanoyl-L-Tyr-L-Ile
a dipeptide derivative from Ang IV, a strong cognitive enhancer and enzyme inhibitor
N-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-isoleucyl-L-histidyl-L-prolyl-L-phenylalanine
-
-
N2-(2- 8[(1-amino-3-phenylpropyl)(hydroxy)phosphoryl]methyl]-4-methylpentanoyl)-L-lysyl-L-histidyl-L-histidyl-L-alanyl-L-phenylalanyl-L-seryl-L-phenylalanyl-L-lysine
i.e. DG025, an antigenic peptide precursor analogue, enzyme binding structure determination and analysis. The canonical orientation of the two N-terminal residues of DG025 is defined by the transition state nature of the ligand and the hydrophobic and aromatic interactions of the hPhe residue in the S1 specificity pocket of the enzyme (and in particular with Phe544). The remaining of the peptide extends toward the base of the cavity, where it is sandwiched between domains II and IV
N2-(4-amino-3-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-ornithine
-
[(5R)-6-amino-5-benzyl-2-(2,2-diphenylethyl)-3,6-dioxohexyl][(1R)-1-amino-3-phenylpropyl]phosphinic acid
i.e. DG026, a phosphinic pseudotripeptide that acts as very potent inhibitor of IRAP. DG026 is able to selectively downregulate IRAP-dependent cross-presentation by dendritic cells but leave ERAP1-dependent cross-presentation unaffected. Enzyme binding structure determination and analysis, overview
[2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromen-3-yl](phenyl)methanone
-
50% inhibition at 100 microM
[2-[([[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]amino)methyl]phenyl]acetic acid
-
-
[2-[([[3-amino-5-(4-hydroxybenzyl)phenyl]carbonyl]amino)methyl]phenyl]acetic acid
-
-
1,10-phenanthroline
-
competition between 1,10-phenanthroline and the substrate only in presence of EDTA. Inhibitory effect of EDTA plus 1,10-phenanthroline can be completely reversed by Zn2+. Ca2+ and Mg2+ increase the potency of Zn2+ for this process
1,10-phenanthroline
-
IC50: 0.2 mM. Inhibitory effect is substantially potentiated by both EDTA and EGTA. A combined and complete inhibition of the enzyme activity by 0.1 mM EDTA and 0.1 mM 1,10-phenanthroline can be prevented in the presence of 0.04-0.1 mM ZnCl2
4-bromo-5-chloro-N-methyl-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
-
-
4-bromo-5-chloro-N-methyl-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
-
4-bromo-5-chloro-N-[3-(1-methyl-1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
-
-
4-bromo-5-chloro-N-[3-(1-methyl-1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
-
4-bromo-5-chloro-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
-
-
angiotensin IV
AngIV, induces an increase in the intracellular calcium concentration in pinealocytes by 72% at 10 nM, but AngIV does not alter cAMP levels
angiotensin IV
IRAP ligands are on the one hand competitive inhibitors of the enzymatic activity of IRAP and on the other hand regulators of its trafficking
L-Val-L-Tyr-L-Ile-L-His-L-Pro-L-Phe
-
i.e. angiotensin IV, adopts a gamma-turn in the C-terminal of its bioactive conformation
additional information
-
inhibitory potency in decreasing order: angiotensin III, angiotensin IV, LVV-hemorphin 7, divalinal/angiotensin IV, angiotensin II, angiotensin 4-8
-
additional information
-
inhibitory potency in decreasing order: angiotensin IV, angiotensin III, LVV-hemorphin 7, divalinal/angiotensin IV, angiotensin 4-8, angiotensin III
-
additional information
-
inhibitory potency in decreasing order: angiotensin IV, angiotensin III, divalinal/angiotensin IV, LVV-hemorphin 7, angiotensin 4-8, angiotensin III
-
additional information
inhibition of insulin-regulated aminopeptidase (IRAP) by aryl sulfonamides, structural basis, docking and moelling, molecular dynamics simulations, overview. The fluorinated series exhibit high metabolic stability in microsomes and encompasses compounds with submicromolar affinity. The binding modes are thoroughly examined by molecular dynamics (MD)-related methods for binding affinity estimation for the whole series of aryl sulfonamides
-
additional information
-
inhibition of insulin-regulated aminopeptidase (IRAP) by aryl sulfonamides, structural basis, docking and moelling, molecular dynamics simulations, overview. The fluorinated series exhibit high metabolic stability in microsomes and encompasses compounds with submicromolar affinity. The binding modes are thoroughly examined by molecular dynamics (MD)-related methods for binding affinity estimation for the whole series of aryl sulfonamides
-
additional information
virtual screening from three-dimensional structure models for transition state analogue inhibitors of IRAP based on quantum mechanically derived reaction coordinates, overview. Transition state and high energy intermediate mimetics have the potential to be very potent enzyme inhibitors. Method development and evaluation
-
additional information
enzyme IRAP undergoes a conformational change upon inhibitor binding, docking study. Analysis of structural determinants for inhibitor selectivity, overview. Significant affinity is generated by structural elements common to all homologous enzymes: the active-site Zn(II) atom, the catalytic Tyr549 and Glu465, N-terminus recognition by Glu295, Glu431, and Glu487, and the S1 specificity residue Phe544
-
additional information
-
inhibitory potency in decreasing order: angiotensin IV, angiotensin III, divalinal/angiotensin IV, LVV-hemorphin 7, angiotensin 4-8, angiotensin III
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Insulin
insulin activates the enzyme migration from the intracellular vesicles to the cellular membrane
-
Insulin
insulin effectively stimulates CysAP activity trafficking from low (LDM) density microsomes toward plasma membrane in all animal groups under study, while the insulin-stimulated traffic of LeuAP activity in adipocytes does not change as a function of metabolic challenges applied
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0033
(2-[[(1-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-prolyl)amino]methyl]phenyl)acetic acid
-
-
0.0074
(2-[[(1-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-prolyl)amino]methyl]phenyl)acetic acid
-
-
0.0014
(2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-isoleucyl)amino]methyl]phenyl)acetic acid
-
-
0.0039
(2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-leucyl)amino]methyl]phenyl)acetic acid
-
-
0.0013
(2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-isoleucyl)amino]methyl]phenyl)acetic acid
-
-
97
(2-[[(N-[[3-amino-5-(4-hydroxybenzyl)phenyl]carbonyl]-L-isoleucyl)amino]methyl]phenyl)acetic acid
-
-
0.05
2-amino-4-(3,4-dimethoxyphenyl)-7-hydroxy-4H-chromene-3-carbonitrile
-
pH 7.4, 37°C
0.1
2-amino-4-(3,5-dimethoxyphenyl)-7-hydroxy-4H-chromene-3-carbonitrile
-
value above, pH 7.4, 37°C
0.1
2-amino-4-[4-(dimethylamino)phenyl]-7-hydroxy-4H-chromene-3-carbonitrile
-
value above, pH 7.4, 37°C
0.1
2-amino-7-hydroxy-4-(3,4,5-trimethoxyphenyl)-4H-chromene-3-carbonitrile
-
value above, pH 7.4, 37°C
0.1
2-amino-7-hydroxy-4-(3-methoxyphenyl)-4H-chromene-3-carbonitrile
-
value above, pH 7.4, 37°C
0.1
2-amino-7-hydroxy-4-(4-methoxyphenyl)-4H-chromene-3-carbonitrile
-
value above, pH 7.4, 37°C
0.1
2-amino-7-hydroxy-4-(pyridin-4-yl)-4H-chromene-3-carbonitrile
-
value above, pH 7.4, 37°C
0.004
2-methoxyethyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.0063
2-[[(1-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-prolyl)amino]methyl]benzoic acid
-
-
0.012
2-[[(1-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-prolyl)amino]methyl]benzoic acid
-
-
0.0018
2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-isoleucyl)amino]methyl]benzoic acid
-
-
0.0037
2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-leucyl)amino]methyl]benzoic acid
-
-
0.0013
2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-isoleucyl)amino]methyl]benzoic acid
-
-
0.00006
angiotensin IV
-
in 50 mM Tris-HCl (pH 7.4), 140 mM NaCl, 0.1% (w/v) bovine serum albumin, and 0.1 mM phenylmethylsulfonyl fluoride, at 37°C
0.0017
benzyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.0026
butyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.00048
ethyl 2-(acetylamino)-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.00003
ethyl 2-(acetylamino)-7-hydroxy-4-(quinolin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.014
ethyl 2-amino-4-(2,4-dichloropyridin-3-yl)-7-hydroxy-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.1
ethyl 2-amino-4-(2-cyanophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
value above, pH 7.4, 37°C
0.0062
ethyl 2-amino-4-(3,4-dimethoxyphenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.035
ethyl 2-amino-4-(3-chlorophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.0032
ethyl 2-amino-4-(3-cyanophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.1
ethyl 2-amino-4-(4-bromophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
value above, pH 7.4, 37°C
0.1
ethyl 2-amino-4-(4-chlorophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
value above, pH 7.4, 37°C
0.011
ethyl 2-amino-4-(4-cyanophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.003
ethyl 2-amino-4-(5,8-dihydroquinolin-2-yl)-7-hydroxy-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.1
ethyl 2-amino-4-(pyridin-3-yl)-4H-benzo[g]chromene-3-carboxylate
-
value above, pH 7.4, 37°C
0.1
ethyl 2-amino-4-(pyridin-3-yl)-4H-benzo[h]chromene-3-carboxylate
-
value above, pH 7.4, 37°C
0.0053
ethyl 2-amino-4-[4-(dimethylamino)phenyl]-7-hydroxy-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.0056
ethyl 2-amino-6-chloro-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.042
ethyl 2-amino-7-hydroxy-4-(2-nitrophenyl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.1
ethyl 2-amino-7-hydroxy-4-(4-methylphenyl)-4H-chromene-3-carboxylate
-
value above, pH 7.4, 37°C
0.0077
ethyl 2-amino-7-hydroxy-4-(4-nitrophenyl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.0029
ethyl 2-amino-7-hydroxy-4-(pyridin-2-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.0018
ethyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.0037
ethyl 2-amino-7-hydroxy-4-(pyridin-4-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.00036
ethyl 2-amino-7-hydroxy-4-(quinolin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.0009
ethyl 2-amino-7-hydroxy-4-(quinolin-4-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.1
ethyl 2-amino-7-hydroxy-4-phenyl-4H-chromene-3-carboxylate
-
value above, pH 7.4, 37°C
0.1
ethyl 2-amino-7-hydroxy-4-[4-(pyridin-2-yl)phenyl]-4H-chromene-3-carboxylate
-
value above, pH 7.4, 37°C
0.0098
ethyl 2-amino-8-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.0049
methyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.0012
N-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-isoleucyl-L-histidyl-L-prolyl-L-phenylalanine
-
-
0.0016
propyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.0119
tert-butyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
16
[2-[([[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]amino)methyl]phenyl]acetic acid
-
-
35
[2-[([[3-amino-5-(4-hydroxybenzyl)phenyl]carbonyl]amino)methyl]phenyl]acetic acid
-
-
additional information
additional information
inhibition kinetics and thermodynamics
-
additional information
additional information
-
inhibition kinetics and thermodynamics
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.2
1,10-phenanthroline
Cricetulus griseus
-
IC50: 0.2 mM. Inhibitory effect is substantially potentiated by both EDTA and EGTA. A combined and complete inhibition of the enzyme activity by 0.1 mM EDTA and 0.1 mM 1,10-phenanthroline can be prevented in the presence of 0.04-0.1 mM ZnCl2
0.022
1-methyl-N-[3-(1H-tetrazol-5-yl)phenyl]-1H-indole-6-sulfonamide
Cricetulus griseus
-
pH 7.4, temperature not specified in the publication
0.0029
2,4,5-trichloro-N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
Cricetulus griseus
-
pH 7.4, temperature not specified in the publication
0.0011
3,4-dichloro-N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
Cricetulus griseus
-
pH 7.4, temperature not specified in the publication
0.0031
3,4-dimethyl-N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
Cricetulus griseus
-
pH 7.4, temperature not specified in the publication
0.125
3-([(4-bromo-5-chlorothiophen-2-yl)sulfonyl]amino)-N-methylbenzamide
Cricetulus griseus
-
pH 7.4, temperature not specified in the publication
0.0018
4,5-dichloro-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
Cricetulus griseus
-
pH 7.4, temperature not specified in the publication
0.034
4-amino-3-(L-arginylamino)benzoic acid
Homo sapiens
pH and temperature not specified in the publication
0.01
4-amino-3-(L-tyrosylamino)benzoic acid
Homo sapiens
pH and temperature not specified in the publication
0.01
4-amino-3-[(O-benzyl-L-tyrosyl)amino]benzoic acid
Homo sapiens
pH and temperature not specified in the publication
0.0079
4-bromo-2,6-difluoro-N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
Cricetulus griseus
-
pH 7.4, temperature not specified in the publication
0.0016
4-bromo-2-fluoro-N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
Cricetulus griseus
-
pH 7.4, temperature not specified in the publication
0.058
4-bromo-5-chloro-N-methyl-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
Cricetulus griseus
-
pH 7.4, temperature not specified in the publication
0.125
4-bromo-5-chloro-N-[3-(1-methyl-1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
Cricetulus griseus
-
pH 7.4, temperature not specified in the publication
0.067
4-bromo-5-chloro-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-carboxamide
Cricetulus griseus
-
pH 7.4, temperature not specified in the publication
0.0021
4-bromo-5-chloro-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
Cricetulus griseus
-
pH 7.4, temperature not specified in the publication
0.0013
7-chloro-N-[3-(1H-tetrazol-5-yl)phenyl]-1,3-dihydro-2,1,3-benzoxadiazole-4-sulfonamide
Cricetulus griseus
-
pH 7.4, temperature not specified in the publication
0.0024
benzyl N-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-tryptophanate
Homo sapiens
pH and temperature not specified in the publication
0.014
benzyl N-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-valinate
Homo sapiens
pH and temperature not specified in the publication
0.0013
benzyl N-(4-amino-3-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-tryptophanate
Homo sapiens
pH and temperature not specified in the publication
0.0037
benzyl N-[3-amino-4-(L-leucylamino)benzoyl]-L-tryptophanate
Homo sapiens
pH and temperature not specified in the publication
0.000438
benzyl N-[3-amino-4-(L-norleucylamino)benzoyl]-L-tryptophanate
Homo sapiens
pH and temperature not specified in the publication
0.0039
benzyl N-[3-amino-4-(L-norleucylamino)benzoyl]-L-valinate
Homo sapiens
pH and temperature not specified in the publication
0.0034
benzyl N-[3-amino-4-([(2S)-2-amino-4-[4-(benzyloxy)phenyl]butanoyl]amino)benzoyl]-L-tryptophanate
Homo sapiens
pH and temperature not specified in the publication
0.0038
benzyl N-[3-amino-4-[(O-benzyl-L-tyrosyl)amino]benzoyl]-L-tryptophanate
Homo sapiens
pH and temperature not specified in the publication
0.001
benzyl N-[4-amino-3-(D-norleucylamino)benzoyl]-L-valinate
Homo sapiens
pH and temperature not specified in the publication
0.000105
benzyl N-[4-amino-3-(L-norleucylamino)benzoyl]-L-tryptophanate
Homo sapiens
pH and temperature not specified in the publication
0.0071
benzyl N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-tryptophanate
Homo sapiens
pH and temperature not specified in the publication
0.012
benzyl N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-valinate
Homo sapiens
pH and temperature not specified in the publication
0.000933
benzyl N-[4-amino-3-[(O-benzyl-L-tyrosyl)amino]benzoyl]-L-tryptophanate
Homo sapiens
pH and temperature not specified in the publication
0.0396
methyl 3-amino-4-(L-arginylamino)benzoate
Homo sapiens
pH and temperature not specified in the publication
0.0033
methyl 3-amino-4-(L-norleucylamino)benzoate
Homo sapiens
pH and temperature not specified in the publication
0.0083
methyl 3-amino-4-(L-tyrosylamino)benzoate
Homo sapiens
pH and temperature not specified in the publication
0.0017
methyl 3-amino-4-[(O-benzyl-L-tyrosyl)amino]benzoate
Homo sapiens
pH and temperature not specified in the publication
0.031
methyl 3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoate
Homo sapiens
pH and temperature not specified in the publication
0.014
methyl 4-amino-3-(L-arginylamino)benzoate
Homo sapiens
pH and temperature not specified in the publication
0.0072
methyl 4-amino-3-(L-norleucylamino)benzoate
Homo sapiens
pH and temperature not specified in the publication
0.057
methyl 4-amino-3-(L-tyrosylamino)benzoate
Homo sapiens
pH and temperature not specified in the publication
0.0021
methyl 4-amino-3-([(2S)-2-amino-4-[4-(benzyloxy)phenyl]butanoyl]amino)benzoate
Homo sapiens
pH and temperature not specified in the publication
0.01
methyl 4-amino-3-[(O-benzyl-L-tyrosyl)amino]benzoate
Homo sapiens
pH and temperature not specified in the publication
0.012
methyl 4-amino-3-[[(2S)-2-amino-4-(4-hydroxyphenyl)butanoyl]amino]benzoate
Homo sapiens
pH and temperature not specified in the publication
0.0013
methyl N-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-tyrosinate
Homo sapiens
pH and temperature not specified in the publication
0.0036
methyl N-(4-amino-3-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-tyrosinate
Homo sapiens
pH and temperature not specified in the publication
0.0022
methyl N-[3-amino-4-(L-arginylamino)benzoyl]-L-tyrosinate
Homo sapiens
pH and temperature not specified in the publication
0.0036
methyl N-[3-amino-4-(L-norleucylamino)benzoyl]-L-tyrosinate
Homo sapiens
pH and temperature not specified in the publication
0.0037
methyl N-[3-amino-4-(L-tyrosylamino)benzoyl]-L-tyrosinate
Homo sapiens
pH and temperature not specified in the publication
0.0029
methyl N-[3-amino-4-[(O-benzyl-L-tyrosyl)amino]benzoyl]-L-tyrosinate
Homo sapiens
pH and temperature not specified in the publication
0.0012
methyl N-[4-amino-3-(D-norleucylamino)benzoyl]-D-tyrosinate
Homo sapiens
pH and temperature not specified in the publication
0.000966
methyl N-[4-amino-3-(L-arginylamino)benzoyl]-D-tyrosinate
Homo sapiens
pH and temperature not specified in the publication
0.1
methyl N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-threoninate
Homo sapiens
pH and temperature not specified in the publication
0.022
methyl N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-tyrosinate
Homo sapiens
pH and temperature not specified in the publication
0.0025
methyl N2-(3,4-diaminobenzoyl)-L-argininate
Homo sapiens
pH and temperature not specified in the publication
0.1
methyl N2-(3,4-diaminobenzoyl)-L-lysinate
Homo sapiens
pH and temperature not specified in the publication
0.0047
methyl N2-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-argininate
Homo sapiens
pH and temperature not specified in the publication
0.02
methyl N2-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-lysinate
Homo sapiens
pH and temperature not specified in the publication
0.0107
methyl N2-(4-amino-3-[[(2S)-2-amino-4-(4-hydroxyphenyl)butanoyl]amino]benzoyl)-L-lysinate
Homo sapiens
pH and temperature not specified in the publication
0.01
methyl N2-(4-amino-3-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-lysinate
Homo sapiens
pH and temperature not specified in the publication
0.0049
methyl N2-[3-amino-4-(L-arginylamino)benzoyl]-L-lysinate
Homo sapiens
pH and temperature not specified in the publication
0.1
methyl N2-[3-amino-4-(L-leucylamino)benzoyl]-L-lysinate
Homo sapiens
pH and temperature not specified in the publication
0.0357
methyl N2-[3-amino-4-(L-norleucylamino)benzoyl]-L-lysinate
Homo sapiens
pH and temperature not specified in the publication
0.07
methyl N2-[3-amino-4-(L-tyrosylamino)benzoyl]-L-lysinate
Homo sapiens
pH and temperature not specified in the publication
0.031
methyl N2-[4-amino-3-(L-norleucylamino)benzoyl]-D-argininate
Homo sapiens
pH and temperature not specified in the publication
0.1
methyl N2-[4-amino-3-(L-norleucylamino)benzoyl]-L-lysinate
Homo sapiens
pH and temperature not specified in the publication
0.0057
methyl N2-[4-amino-3-([(2S)-2-amino-4-[4-(benzyloxy)phenyl]butanoyl]amino)benzoyl]-L-lysinate
Homo sapiens
pH and temperature not specified in the publication
0.1
N-(3,4-diaminobenzoyl)-L-tryptophan
Homo sapiens
pH and temperature not specified in the publication
0.0052
N-(3-amino-4-[[(2S)-2-amino-4-(4-hydroxyphenyl)butanoyl]amino]benzoyl)-L-tryptophan
Homo sapiens
pH and temperature not specified in the publication
0.02
N-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-valine
Homo sapiens
pH and temperature not specified in the publication
0.0044
N-(4-amino-3-[[(2R)-2-amino-4-(4-hydroxyphenyl)butanoyl]amino]benzoyl)-L-tryptophan
Homo sapiens
pH and temperature not specified in the publication
0.016
N-[3-(1H-tetrazol-5-yl)phenyl]-1-benzothiophene-2-sulfonamide
Cricetulus griseus
-
pH 7.4, temperature not specified in the publication
0.039
N-[3-(1H-tetrazol-5-yl)phenyl]-2-benzothiophene-4-sulfonamide
Cricetulus griseus
-
pH 7.4, temperature not specified in the publication
0.125
N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
Cricetulus griseus
-
pH 7.4, temperature not specified in the publication
0.044
N-[3-(1H-tetrazol-5-yl)phenyl]biphenyl-4-sulfonamide
Cricetulus griseus
-
pH 7.4, temperature not specified in the publication
0.125
N-[3-(1H-tetrazol-5-yl)phenyl]pyridine-3-sulfonamide
Cricetulus griseus
-
pH 7.4, temperature not specified in the publication
0.125
N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
Cricetulus griseus
-
pH 7.4, temperature not specified in the publication
0.0076
N-[3-amino-4-(L-arginylamino)benzoyl]-L-tryptophan
Homo sapiens
pH and temperature not specified in the publication
0.0017
N-[3-amino-4-(L-norleucylamino)benzoyl]-L-tryptophan
Homo sapiens
pH and temperature not specified in the publication
0.1
N-[3-amino-4-(L-norleucylamino)benzoyl]-L-valine
Homo sapiens
pH and temperature not specified in the publication
0.0013
N-[3-amino-4-(L-tyrosylamino)benzoyl]-L-tryptophan
Homo sapiens
pH and temperature not specified in the publication
0.1
N-[4-amino-3-(D-norleucylamino)benzoyl]-L-valine
Homo sapiens
pH and temperature not specified in the publication
0.000655
N-[4-amino-3-(L-arginylamino)benzoyl]-L-tryptophan
Homo sapiens
pH and temperature not specified in the publication
0.0033
N-[4-amino-3-(L-arginylamino)benzoyl]-L-valine
Homo sapiens
pH and temperature not specified in the publication
0.000296
N-[4-amino-3-(L-norleucylamino)benzoyl]-L-tryptophan
Homo sapiens
pH and temperature not specified in the publication
0.1
N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-tryptophan
Homo sapiens
pH and temperature not specified in the publication
0.1
N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-valine
Homo sapiens
pH and temperature not specified in the publication
0.0000077
N2-(2- 8[(1-amino-3-phenylpropyl)(hydroxy)phosphoryl]methyl]-4-methylpentanoyl)-L-lysyl-L-histidyl-L-histidyl-L-alanyl-L-phenylalanyl-L-seryl-L-phenylalanyl-L-lysine
Homo sapiens
pH 7.0, 37°C, recombinant wild-type enzyme
0.1
N2-(4-amino-3-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-ornithine
Homo sapiens
pH and temperature not specified in the publication
0.0041
N2-[4-amino-3-(L-leucylamino)benzoyl]-L-lysine
Homo sapiens
pH and temperature not specified in the publication
0.0038
N2-[4-amino-3-(L-phenylalanylamino)benzoyl]-L-lysine
Homo sapiens
pH and temperature not specified in the publication
0.0048
N2-[4-amino-3-(L-tyrosylamino)benzoyl]-L-lysine
Homo sapiens
pH and temperature not specified in the publication
0.0099
methyl N-(3,4-diaminobenzoyl)-L-tyrosinate
Homo sapiens
pH and temperature not specified in the publication
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
6.5
7.4
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
7 - 8
-
pH 7.0: about 15% of activity maximum, pH 8.0: about 10% of activity maximum
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
37
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
isolated from Tecopa Bor, a small, thermal spring habitat adjacent to the Amargosa River near Tecopa, California, USA
UniProt
brenda
-
35899, 35900, 35903, 35904, 35905, 35906, 35907, 35908, 35911, 35919, 651074, 651116, 664275, 667810, 667811, 667887, 667888, 668752, 668753, 668760, 670127, 670450, 670742, 670859, 683204, 683302, 683431, 683795, 683806, 684051, 696727, 699736, 732310
-
-
brenda
-
-
-
brenda
Otsuka Long Evans Tokushima Fatty rats, model of type II Diabetes mellitus
-
-
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
-
trophoblastic cell. Insulin induces enzyme expression in trophoblasts
brenda
N-methyl nitrosourea (NMU)-induced breast cancer
brenda
-
P-LAP is detected in all clear-cell adenocarcinomas
brenda
-
P-LAP is detected in 15 of 17 endometrioid adenocarcinomas
brenda
-
high activity in the inner mucosal lining of the ampulla segment of the Fallopian tube, lower level in the interstitial and isthmus
brenda
-
highest concentration in the outer myometrial layer of the uterus, lower levels in the inner myometrial layer and in the luminal epithelium
brenda
-
enzyme in soluble fraction, no activity detected in particulate fraction
brenda
-
P-LAP is located in the periphery in early gestation, located in both the periphery and inner cells during mid-gestation, located only in inner cells in late gestation
brenda
-
P-LAP is detected in 13 of 14 mucinous adenocarcinomas
brenda
-
P-LAP is detected in 7 of 14 borderline tumors
brenda
-
expression of the enzyme is increased during the differentiation of the cells into neuronal cells
brenda
-
cystinyl aminopeptidase is 100% higher in the left than in the right prefrontal cortex
brenda
-
tendency towards increased P-LAP expression with advancing grade is observed in serous adenocarcinomas
brenda
additional information
-
low activity, enzyme in soluble fraction, no activity detected in particulate fraction
brenda
-
during normal pregnancy, enzyme activity in maternal serum gradually increases to the maximum at near term
brenda
-
type III integral membrane protein, converted to a soluble form existing in maternal serum by metalloproteases
brenda
-
activity is greatly increased in rats with mammary tumors. The activity may be involved in the promotion and progression of breast cancer through oxytocin, vasopressin and/or renin-angiotensin system misregulation
brenda
-
highly expressed in selected olfactory regions, in septal and hypothalamic nuclei, throughout the hippocampal formation and cerebral cortex, and in motor and motor associated nuclei. IRAP is expressed exclusively in neurons in these regions
brenda
AT4 receptor/IRAP is found in neurons in the cortex, hippocampus and basal ganglia
brenda
-
P-LAP is an independent prognosticator of clinical outcome in patients with endometrial carcinoma. Assessment of the P-LAP status provides clinically useful prognostic information in patients with endometrial carcinoma
brenda
-
the enzyme is suggested to be involved in reducing chemosensitivity and may be a therapeutic target in endometrial carcinoma
brenda
-
immunodetection of enzyme with large 100-200 nm vesicles in hippocampal neurons
brenda
-
cystinyl aminopeptidase is 300% higher in the left than in the right hippocampus
brenda
-
colocalization with the potential in vivo substrates, oxytocin and vasopression
brenda
-
located in distal and collecting tubules but not in proximal tubules
brenda
-
treatment with cyclosporin increases the activity of cystyl aminopeptidase as well as neutral, basic, prolyl imino and pyroglutamyl soluble aminopeptidase in the renal cortex
brenda
-
low activity, enzyme in soluble fraction, no activity detected in particulate fraction
brenda
-
among hematopoietic cells in fetal liver only megakaryocytes show strong expression of P-LAP
brenda
-
enzyme in soluble fraction, no activity detected in particulate fraction
brenda
expressed in magnocellular neurones of the supraoptic (SON) and paraventricular (PVN) nuclei
brenda
-
high activity level in corpus albicans, lower activity throughout the ovarian cortex and the surrounding connective tissue
brenda